Nasdaq Stockholm’s listing committee has decided that Xbrane Biopharma AB fulfills the requirements for admission to trading of the company’s shares on the main market Nasdaq Stockholm.
The first day of trading of Xbrane’s shares on Nasdaq Stockholm is expected to be Monday 23 September 2019. The last day of trading of Xbrane’s shares on Nasdaq First North Growth Market is expected to be Friday 20 September 2019.
“Up-listing to the main market, Nasdaq Stockholm, is an important step for Xbrane. It increases the potential investor base and thus creates greater opportunities for us to become a world-leading biosimilar developer,” says Martin Åmark, CEO Xbrane.
Photo of Martin Åmark: Peter Phillips